Back to search results
NCT06048133

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

Active, Not Recruiting
PHASE2Ages 18+InterventionalTreatment
Nataliya Uboha
~33 participants
Updated 2026-08-17 on ClinicalTrials.gov
What's tested:GemcitabineCisplatinZimberelimabQuemliclustat

At a glance

Recruiting sites
0 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Estimate the progression free survival (PFS) with gemcitabine, cisplatin, quemliclustat (AB680) and zimberelimab (AB122) in patients with advanced BTCs.
Measured over 2 years

Conditions

Biliary Tract Carcinoma
Cholangiocarcinoma
Bile Duct Cancer

Explore related trials

Biliary Tract Carcinoma

NCT06048133

Where you'd take part

This study runs at 4 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center

    Indianapolis, Indianano site contact published

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jerseyno site contact published

  • University of Michigan Health System

    Ann Arbor, Michiganno site contact published

  • University of Wisconsin

    Madison, Wisconsinno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Nataliya Uboha, MD, PhD · PRINCIPAL_INVESTIGATOR · University of Wisconsin, Madison

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Interstitial lung disease, including history of interstitial lung disease or non-infectious pneumonitis.
Active viral, bacterial, or fungal infections requiring parenteral treatment within 14 days of the initiation of the study treatments. 9. History of trauma or major surgery within 28 days prior to the first dose of IP. (Note that placement of central venous access catheter (e.g., port or similar) is not considered a major surgical procedure. 10. Treatment with palliative radiation therapy within 14 days of study treatment initiation. 11. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. 12. Significant dementia or other mental condition that precludes the participant's ability to consent to the study. 13. Use of any live vaccines against infectious diseases within 4 weeks (28 days) of initiation of investigational products.

What this trial measures

  • Estimate the progression free survival (PFS) with gemcitabine, cisplatin, quemliclustat (AB680) and zimberelimab (AB122) in patients with advanced BTCs.2 years

    Progression free survival (PFS), as determined by RECIST v1.1, is defined as the time from study registration to the date of documented disease progression or death from any cause.